– 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 – – On track to dose first patient in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 – – Dosing in Phase 2 trial of atebimetinib + Libtayo® in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 – – Ended 2025 with $217 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 – NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) — Immuneering...

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration On-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026 Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measures Cash runway through the planned early-2029 topline readouts from both Phase 3 pivotal studies Virtual Investor Day scheduled for March 6, 2026NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) — AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,...

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human clinical trial in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027 Third development candidate, JADE301, nominated; Phase 1 clinical trial expected to commence in the first half of 2027 $336 million of cash, cash equivalents, and investments as of December 31st, 2025 expected to provide runway into the first half of 2028SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO),...

Press Release Full Year 2025 Results:Atos Group has Delivered on its Commitments to Restore its Foundations Growth Chapter Ready to be OpenedFY 2025 financial and extra financial targets met or exceeded:Revenue at €8,001 million, reflecting a clear improvement in the organic growth trajectory in Q4 Operating margin at €351 million, representing 4.4% of revenue, doubling year-on-year Net change in cash1 limited to €-326 million despite faster than expected execution of the restructuring program Greenhouse gas emissions reduced by 58% compared with the 2019 baseline.Execution of Genesis strategic and transformation plan ahead of schedule, with 88%2 of the three-year savings target completed in less than one year Strengthened commercial traction, with early signs of renewed client confidence Scaling artificial intelligence (AI) from...

High-quality performance with outstanding cash generation Upgraded mid-term margin target Governance evolution, ensuring smooth transition and full strategic continuityCergy, March 6th, 2026 Record profitability and solid revenue growth, pushing revenue well above the €10 bn markRevenue: €10,380 million, up +4.8% vs. 2024, including +3.2% growth from acquisitions and +2.0% organic growth, with Germany confirmed as the Group’s primary growth driver (+5.3%), well supported by North-Western Europe (+4.3%) EBITA increased sharply by 11.4% to €793 million, with the margin reaching a record 7.6% (+40 bps), driven by pricing power, selectivity, operational excellence and accretive acquisitions Adjusted net income1:  €458 million (+9% vs. 2024) Recommended dividend: €1.08 per share2, up 8%  Another year of outstanding free cash flow€524...

Transitioned to a pure-play industrial REIT; Attractive development properties completed; Strong leasing activity TORONTO, March 05, 2026 (GLOBE NEWSWIRE) — Nexus Industrial REIT (the “REIT”) (TSX: NXR.UN) announced today its results for the fourth quarter and year ended December 31, 2025. “2025 was a transformative year for Nexus, and I am very pleased with the results” said Kelly Hanczyk, CEO of Nexus Industrial REIT. We kept a long-term focus, completing our strategic transition to become the only scale, Canada-focused industrial REIT, and completed two value-accretive projects, adding 440,000 square feet of GLA that will deliver an unlevered return of 9.4% on development costs. We also acquired two well-located, high-quality buildings in Montreal initially contributing $2.6 million in annual NOI with significant mark-to-market...

CALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) — Badger Infrastructure Solutions Ltd. (“Badger”, the “Company”, “we”, “our” or “us”) (TSX:BDGI) reported fourth quarter and 2025 annual results today. All results are presented in U.S. dollars unless otherwise stated. 2025 FOURTH QUARTER AND ANNUAL FINANCIAL AND OPERATIONAL HIGHLIGHTSThe Company achieved revenue of $213.5 million for the quarter and $831.7 million for the year, up 14% and 12%, respectively, from 2024. Adjusted EBITDA(1) improved to $44.9 million for the quarter and $198.2 million for the year, up 2% and 13%, respectively, from 2024. Adjusted net earnings per share(1) was $0.34 per share for the quarter and improved to $2.04 per share for the year, up 21% from 2024. Revenue per truck per month (“RPT”)(1) for the quarter and the year was $41,756 and $41,672, respectively,...

VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) — Canfor Corporation (“the Company” or “Canfor”) (TSX: CFP) today reported its fourth quarter of 2025 results: Overview.For the fourth quarter of 2025, the Company reported an operating loss of $415.9 million and a net loss of $390.5 million, equivalent to $3.35 per share. An asset write-down and impairment charge of approximately $320.4 million has been recorded in Q4 2025 (including a $52.5 million write off of a previously recognized deferred tax asset), of which $213.9 million relates to the Company’s lumber segment and $106.5 million relates to the pulp and paper segment. After taking into consideration adjusting and one-time items1 of $270.9 million, the adjusted operating loss for Q4 2025 was $145.0 million, compared to a similarly adjusted operating loss...

VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) — Canfor Pulp Products Inc. (“The Company” or “CPPI”) (TSX: CFX) today reported its fourth quarter of 2025 results: Overview.Q4 2025 operating loss of $85.6 million; net loss of $133.6 million, or $2.05 per share.As a result of the prolonged weakness in global pulp markets and the Company’s persistent challenges accessing economically viable fibre, an asset write-down and impairment charge totaling $106.5 million was recognized in Q4 2025, which included a write-off of a previously recognized deferred tax asset of $52.5 million.After taking into consideration adjusting and one-time items1 totaling $57.5 million, the adjusted operating loss for Q4 2025 was $28.1 million, compared to a similarly adjusted operating loss of $11.1 million in Q3 2025.Global softwood...

CALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) — Wilmington Capital Management Inc. (TSX: WCM.A, WCM.B) (“Wilmington” or the “Corporation”) reports its fourth quarter and year end December 31, 2025 financial reports and provides an operational update. For the three and twelve months ended December 31, 2025, the Corporation reported a net income of $0.2 million or $0.01 per share and a net loss of $0.5 million or ($0.04) per share, compared to a net loss of $0.8 million or ($0.06) per share and net income of $0.4 million or $0.03 per share for the same periods in 2024, respectively.      Outlook As previously reported, beginning in August 2023, the Corporation took steps to monetize a number of its investments in order to unlock the value which had been substantially realized, distribute capital to its shareholders and simplify...